Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial (Q28286240)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial	scientific article

Statements

scholarly article

0 references

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial (English)

0 references

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

randomized experiment

1 reference

based on heuristic

inferred from title

Richard M Bergenstal

1

object named as

Richard M Bergenstal

0 references

author name string

Carol Wysham

2

0 references

Leigh Macconell

3

0 references

Jaret Malloy

4

0 references

Brandon Walsh

5

0 references

Ping Yan

6

0 references

Ken Wilhelm

7

0 references

Jim Malone

8

0 references

Lisa E Porter

9

0 references

language of work or name

0 references

publication date

7 August 2010

0 references

0 references

376

0 references

9739

0 references

431-9

0 references

randomized experiment

0 references

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Does comparative effectiveness have a comparative edge?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative-effectiveness research--implications of the Federal Coordinating Council's report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New, but not improved? Incorporating comparative-effectiveness information into FDA labeling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing weight-related quality of life in obese persons with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960590-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(10)60590-9

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28286240&oldid=1505043821"